Xenetic Biosciences Shares Insights on DNase I Efficacy in Cancer Treatment

Xenetic Biosciences, Inc., a biopharmaceutical company, has shared promising preclinical results in its Virtual Investor "What This Means" segment. Dr. Reid Bissonnette, the Executive Consultant for Translational Research and Development, emphasized data presented at the Society for Immunotherapy of Cancer's 39th Annual Meeting. The findings highlight DNase I's enhancement of anti-CTLA-4 immune checkpoint blockade efficacy in preclinical models of colorectal carcinoma (CRC).

This research is pivotal as MSS/MMRp CRC accounts for 85% of CRC cases where traditional immune checkpoint blockade agents have shown limited effectiveness. The implementation of DNase I in treatment has shown significant improvement, suggesting enhanced outcomes for hard-to-treat cancers. The company remains focused on advancing its DNase platform, particularly for pancreatic carcinoma and other solid tumors.